5th Neuropsychiatric & Psychedelics Drug Development

Kongressthemen
With reports in depression and anxiety escalating and reaching critical levels, the urgency for developing effective, safe, and fast-acting therapeutics in psychiatry has never been greater. Advances in biomarker development, clinical endpoints, discovery platforms, and modelling have brought us to the precipice of breaking through the historical barriers in psychiatric and psychedelic drug development and into a new era of impactful treatments for this underserved community.

Kongressorganizer (PCO)
Hanson Wade

https://go.evvnt.com/1252699-2?pid=4832

Frau Stephanie Nketia